Hans Wildiers, MD, on Metastatic Breast Cancer: Comparing Addition of Eftilagimod Alpha vs Placebo to Paclitaxel
SITC 2021
Hans Wildiers, MD, of University Hospitals Leuven, discusses the final results from the phase IIb AIPAC study, which suggested that eftilagimod added to paclitaxel may be of benefit to patients older than 65 years with hormone receptor–positive, HER2-negative metastatic breast cancer after endocrine-based therapy. Eftilagimod, which is a first-in-class antigen presenting cell activator, appeared to increase circulating CD4/CD8 T cells, which correlated to improved overall survival (Abstract 948).
The ASCO Post Staff
Emily Z. Keung, MD, of The University of Texas MD Anderson Cancer Center, discusses the complex interactions of immune infiltrates and neoadjuvant immune checkpoint blockade (ICB) in patients with resectable soft-tissue sarcoma. These interactions may hold the key to understanding pathologic response to ICB and ICB resistance (Abstract 379).
The ASCO Post Staff
Jeffrey Weber, MD, PhD, of NYU Langone Medical Center, offers his perspective on the impact of the COVID-19 pandemic on oncology care and cancer clinical trials, as clinicians strive to provide optimal treatment to patients while reducing their risk of contracting the coronavirus. The steep decline in trial enrollment has recovered, with many of the changes in how research was conducted as a result of the pandemic still in place and improving the process going forward.
The ASCO Post Staff
John M. Kirkwood, MD, of the University of Pittsburgh Medical Center, discusses phase Ib findings on the combination of vidutolimod plus pembrolizumab, as well as vidutolimod monotherapy, both of which showed clinical activity in patients with PD-1 blockade–refractory melanoma. The duration of response with the combination therapy was substantially longer. Phase II studies are ongoing (Abstract 950).
The ASCO Post Staff
Patrick Hwu, MD, of Moffitt Cancer Center and President of the Society for Immunotherapy of Cancer (SITC), and Mary Dean, JD, CAE, SITC Executive Director, discuss the organization’s mission, strides made in cancer immunology, meeting the challenge of immunoresistance, and the new SITC app for clinical practice guidelines. This app places a useful tool in the hands of health-care providers, one that can be continually updated as the science evolves.
The ASCO Post Staff
Lynda Chin, MD, of the University of Texas, Austin Dell Medical School and Apricity Health, discusses precision medicine, barriers to its progress, and the challenges that must be met to facilitate better outcomes for patients. Building evidence and trust is key, Dr. Chin explains, as is developing an infrastructure that allows more clinicians to take part in the process.
